Fusion Imaging Contrast-enhanced Ultrasound LI-RADS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-30

Study Completion Date

2021-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CEUS LI-RASD apply to lesion visible at precontrast ultrasound but not the lesion invisible. Fusion imaging can use to invisible lesions at precontrast ultrasound in clinical practice. Thus, our aim is to explore the application value of CEUS LI-RADS in contrast-enhanced fusion imaging for focal liver lesions that are not visible on conventional ultrasound in high-risk patients with hepatocellular carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Application Value of CEUS Li-RADS in Hepatic Focal Lesions in Patients With Non-high Risk Factors for HCC

NCT04920214

Hepatocellular Carcinoma

UNKNOWN

Utility of Ultrasound Imaging for Diagnosis of Focal Liver Lesions: A Radiomics Analysis

NCT03871140

Focal Liver Lesions Ultrasonics Intelligent Diagnosis +2 more

UNKNOWN

Radiomics Analysis of Focal Liver Lesions Based on Contrast-Enhanced Ultrasound Imaging

NCT04682886

Focal Liver Lesions Contrast-enhanced Ultrasound

RECRUITING

Effectivity and Safety of Ultrasound-guided Percutaneously Radiofrequency Ablation for Liver Cancer

NCT03026452

Liver Cancer

UNKNOWN PHASE1/PHASE2

Role of CEUS as a Secondary Diagnostic Modality

NCT04494022

Hepatocellular Carcinoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fusion imaging contrast-enhanced ultrasound LI-RADS

Fusion imaging contrast-enhanced ultrasound will be performed in patients with invisible lesion at conventional ultrasound.

Drug: SonoVue

Group Type EXPERIMENTAL

Fusion imaging contrast-enhanced ultrasound

Intervention Type DIAGNOSTIC_TEST

Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.

Drug: SonoVue

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Fusion imaging contrast-enhanced ultrasound

Fusion imaging contrast-enhanced ultrasound will be performed for patients with invisible lesion at conventional ultrasound.

Drug: SonoVue

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients at risk for HCC(Cirrhosis or Chronic hepatitis B viral infection or Current or prior HCC) Suspicious lesions detected by CECT/MRI but not visible on conventional ultrasound and US-CECT/MRI fusion imaging Patients sign the informed consent.

Exclusion Criteria

Patients without risk of HCC(With cirrhosis due to congenital hepatic fibrosis or With cirrhosis due to a vascular disorder such as hereditary hemorrhagic telangiectasia, Budd-Chiari syndrome, chronic portal vein occlusion, cardiac congestion, or diffuse nodular regenerative hyperplasia) Patients without a successful registration or lesions can be seen on conventional ultrasound after successful registration Pregnancy or lactation Patients with pretreat lesion Patients don't sign the informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No